Spots Global Cancer Trial Database for relapsed leukemia
Every month we try and update this database with for relapsed leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | NCT05495035 | Lymphoblastic L... Leukemia, Lymph... Relapsed Leukem... Refractory Leuk... | Olverembatinib,... | 1 Year - 18 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children | NCT02484261 | Leukemia | Bortezomib Pravastatin | 22 Months - 21 Years | Children's National Research Institute | |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | NCT04065399 | Acute Myeloid L... Acute Lymphobla... Mixed Lineage A... Mixed Phenotype... Acute Leukemia ... | revumenib cobicistat | 30 Days - | Syndax Pharmaceuticals | |
| ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | NCT01478074 | Acute Myeloid L... | G-CSF Cytarabine Fludarabine Donor Natural K... ALT-801 | 2 Years - 59 Years | Altor BioScience | |
| Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children | NCT02512926 | Relapsed Solid ... Refractory Soli... Relapsed Leukem... Refractory Leuk... | Carfilzomib Cyclophosphamid... Etoposide | 6 Months - 29 Years | Stanford University | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | NCT05495035 | Lymphoblastic L... Leukemia, Lymph... Relapsed Leukem... Refractory Leuk... | Olverembatinib,... | 1 Year - 18 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | NCT02215629 | Relapsed or Ref... Relapsed or Ref... | VS-4718 | 18 Years - | Verastem, Inc. | |
| JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia | NCT00860522 | Leukemia | JVRS-100 JVRS-100 | 18 Years - | Milton S. Hershey Medical Center | |
| Study of Radiolabeled Revumenib in Adults With Acute Leukemia | NCT05406817 | Acute Leukemia | Revumenib | 18 Years - | Syndax Pharmaceuticals | |
| Study of Radiolabeled Revumenib in Adults With Acute Leukemia | NCT05406817 | Acute Leukemia | Revumenib | 18 Years - | Syndax Pharmaceuticals | |
| A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. | NCT00315705 | Acute Lymphobla... Acute Myelogeno... Relapsed Leukem... | clofarabine Etoposide Cyclophosphamid... | 1 Year - 21 Years | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
